Understanding Tysabri and PML: Risk Factors and Monitoring

Latest update (2026-07)

Tysabri (natalizumab) PML injury claims continue to be evaluated based on individual monitoring and diagnosis records. [source]

From General Health Information to Targeted Risk Awareness

If you or a loved one is taking Tysabri, you may have heard about the risk of progressive multifocal leukoencephalopathy (PML). Decades of pharmacovigilance have established that certain factors, such as JC virus antibody status and duration of therapy, can increase this risk. This page outlines who may be most affected and what monitoring steps are recommended.

Find Out If You Qualify for Compensation →

Medical Evidence Linking Tysabri to PML

Tysabri (natalizumab) is a biologic therapy approved for relapsing forms of multiple sclerosis and Crohn's disease. Its use carries a well-documented risk of progressive multifocal leukoencephalopathy (PML), a severe brain infection caused by the JC virus. For patients in North Carolina who have developed PML after Tysabri treatment, understanding the medical evidence and legal time limits for filing a claim is critical. The FDA-approved prescribing information for Tysabri includes a boxed warning stating that the drug "increases the risk of progressive multifocal leukoencephalopathy (PML), an opportunistic viral infection of the brain that usually leads to death or severe disability" (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). This warning is based on clinical data and postmarketing reports. The label identifies three primary risk factors for PML: the presence of anti-JCV antibodies, longer treatment duration (especially beyond two years), and prior use of immunosuppressants (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). These factors should be considered when initiating or continuing therapy. The mechanism linking Tysabri to PML involves the drug's effect on immune surveillance. Tysabri blocks alpha-4 integrin, preventing immune cells from crossing the blood-brain barrier. This reduces inflammation in the central nervous system but also impairs the brain's ability to control JC virus reactivation. In immunocompromised patients, the virus can infect oligodendrocytes, leading to demyelination and progressive neurological deficits. Clinical presentation of PML includes subacute onset of cognitive changes, motor weakness, visual disturbances, and speech difficulties. Diagnosis typically requires MRI imaging showing characteristic white matter lesions and detection of JC virus DNA in cerebrospinal fluid via PCR.

Adequacy of Warnings and Legal Implications

The adequacy of warnings regarding Tysabri and PML has been a subject of litigation. The prescribing information includes a boxed warning and mandates enrollment in the TOUCH Prescribing Program, which requires patients to read a Medication Guide and sign an enrollment form acknowledging risks (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). However, some plaintiffs have argued that these warnings were insufficient to convey the severity and likelihood of PML, particularly in patients without all three risk factors. The label states that PML "usually leads to death or severe disability" (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962), but the risk-benefit analysis remains complex. For settlement-related considerations, affected patients in North Carolina must be aware of the statute of limitations for product liability claims. In North Carolina, the statute of limitations for personal injury claims is generally three years from the date of injury. However, the "discovery rule" may apply, meaning the clock starts when the plaintiff knew or should have known that the injury was caused by the defendant's product. For PML, this could be the date of diagnosis or when symptoms first appeared. The timeline between Tysabri exposure and documented harm is variable. PML can develop months to years after starting treatment, with the label noting that risk increases with longer duration, especially beyond two years (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). This latency period complicates the determination of when the statute begins. Patients who have been diagnosed with PML after Tysabri use should seek legal counsel promptly to assess their individual circumstances.

Settlement Considerations for North Carolina Patients

The settlement process for Tysabri-related PML claims has involved multidistrict litigation and individual settlements. Factors influencing settlement include the severity of disability, duration of treatment, presence of risk factors, and the adequacy of warnings provided to the patient. Medical records documenting the diagnosis, treatment history, and any prior immunosuppressant use are essential. In summary, the medical evidence clearly establishes that Tysabri increases the risk of PML, with specific risk factors identified. For North Carolina patients, the statute of limitations for filing a claim is typically three years, but the discovery rule may extend this period. Given the severe outcomes associated with PML, timely legal consultation is advised. References (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962)

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Community Resource & Benefit Desk

Request archival records or inquire about member-exclusive transition and benefit programs.

Frequently Asked Questions

What is the statute of limitations for Tysabri-related PML claims in North Carolina?

In North Carolina, the statute of limitations for personal injury claims is generally three years from the date of injury. However, the discovery rule may apply, meaning the clock starts when the plaintiff knew or should have known that the injury was caused by Tysabri. For PML, this could be the date of diagnosis or when symptoms first appeared. It is crucial to consult an attorney promptly to assess your specific situation.

What are the risk factors for developing PML while on Tysabri?

The FDA-approved label identifies three primary risk factors: the presence of anti-JCV antibodies, longer treatment duration (especially beyond two years), and prior use of immunosuppressants (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). These factors should be considered when initiating or continuing therapy.

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Tysabri exposure and a confirmed Progressive Multifocal Leukoencephalopathy diagnosis may request an independent eligibility review. [Begin Assessment]

References

FDA DailyMed Tysabri Label

Find Out If You Qualify for Compensation

Statutes of limitations can limit the time you have to file a claim. A records screening is free and confidential.

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.